Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells

Chihiro Shimazaki, Jens Atzpodien, David Wisniewski, Subhash C. Gulati, Jonathan E. Kolitz, Jerrold Fried, Bayard D. Clarkson

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


We studied the sensitivity of human myeloma (plasma cell leukemia) toward autologous and allogeneic lymphokine-activated killer (LAK) cells. Fresh plasma cell leukemia (PCL)-derived peripheral blood mononuclear cells (PBMC) and PBMC from 3 normal donors were cultured in the presence of recombinant interleukin-2 (rIL2; 1, 000 U/ml) for subsequent use as cytotoxic effectors against fresh and continuously cultured myeloma cells. Target cell lysis was measured in a 4-hour5lCr radioisotope release assay. At an effector to target (E: T) ratio of 50:1, rIL2-induced PCL-PBMC lysed 48 ± 19% (mean ± 1 SD) of autologous myeloma targets, as compared to 89 ±5, 95 ± 15, and 100 ±9% lysis of standard LAK-sensitive Daudi cells and allogeneic myeloma cell lines SKO-007, and RPMI-8226, respectively. Normal PBMC-derived rIL2-induced (LAK) cells exhibited a slightly lower cytotoxic reactivity against allogeneic targets (61 ±9, 60 ±6, and 81 ± 8% cytolysis of SKO-007, RPMI-8226, and Daudi cells, respectively, at a 50:1 E:T ratio). Cytotoxicity against myeloma (PCL) of autologous PCL-derived killer cells could be significantly (at least 2-fold) enhanced when rIL-2- induced effector cells were preincubated for 18 h in the presence of recombinant Interferon-αa rIFN-α; 1, 000 U/ml). In summary, our results indicate the potential antitumor efficacy of rIL2- and rIL2 + rlFN-α-activated killer cells in human myeloma (PCL).

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalActa Haematologica
Issue number4
StatePublished - 1988
Externally publishedYes


  • Interferon-α
  • Interleukin-2
  • Lymphokine-activated killer cells
  • Multiple myeloma


Dive into the research topics of 'Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells'. Together they form a unique fingerprint.

Cite this